04:46 PM EST, 11/25/2024 (MT Newswires) -- Zimmer Biomet Holdings ( ZBH ) said Monday the US Food and Drug Administration approved a premarket approval application supplement for the Oxford cementless partial knee implant.

The regulatory approval is based on safety and effectiveness results from an investigational device exemption study as well as non-clinical testing for cementless partial knee replacement, the company said.

Zimmer said that compared with "partial knee replacements that use bone cement to secure the implant in place, a cementless approach allows patients' natural bone growth to secure the implant for better long-term fixation."

The company said that as part of the product's US launch in Q1 2025, it will provide training that will focus on the "cementless surgical technique and proper patient selection."